Multi-Institutional Survey of Medical Treatment for Late-Onset Hypogonadism in Japan
The adequate criteria for late-onset hypogonadism (LOH) diagnosis, including serum testosterone levels, type (total or free testosterone) and duration of androgen replacement therapy, and evaluations of treatment effectiveness remain controversial. To evaluate the current status of medical treatment...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-03-01
|
| Series: | American Journal of Men's Health |
| Online Access: | https://doi.org/10.1177/1557988316681668 |
| _version_ | 1818502016476905472 |
|---|---|
| author | Hisanori Taniguchi MD PhD Tadashi Matsuda MD |
| author_facet | Hisanori Taniguchi MD PhD Tadashi Matsuda MD |
| author_sort | Hisanori Taniguchi MD PhD |
| collection | DOAJ |
| description | The adequate criteria for late-onset hypogonadism (LOH) diagnosis, including serum testosterone levels, type (total or free testosterone) and duration of androgen replacement therapy, and evaluations of treatment effectiveness remain controversial. To evaluate the current status of medical treatment for LOH in Japan, the first nationwide survey were performed. A total of 35 questionnaires answered by urologists in high-volume facilities were analyzed. The median numbers of patients with hypogonadism-related symptoms per month were 10. Aging Male Symptom Score, International Index of Erectile Function, and International Prostate Symptom Score questionnaires were widely used for questionnaires. The diagnostic criteria for LOH varied. Among the patients who presented with hypogonadism-related symptoms, the mean proportion of patients undergoing treatment for LOH was 62.3%. In Japan, LOH was treated not only with testosterone enanthate injections or testosterone ointment but also with Kampo medicine. In many facilities, LOH treatment effectiveness was assessed after a 3-month period. Efficacy was assessed in different ways. Treatment effectiveness rate ranged from 30% to 80%. The duration of LOH treatment was not fixed and was established individually by both the patient and treating physician. This study showed that the real clinical practices for LOH are very diverse, and a general consensus is needed. |
| first_indexed | 2024-12-10T21:04:10Z |
| format | Article |
| id | doaj.art-eaf872ca38674ff2a361ecbefffe0195 |
| institution | Directory Open Access Journal |
| issn | 1557-9883 1557-9891 |
| language | English |
| last_indexed | 2024-12-10T21:04:10Z |
| publishDate | 2017-03-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | American Journal of Men's Health |
| spelling | doaj.art-eaf872ca38674ff2a361ecbefffe01952022-12-22T01:33:41ZengSAGE PublishingAmerican Journal of Men's Health1557-98831557-98912017-03-011110.1177/1557988316681668Multi-Institutional Survey of Medical Treatment for Late-Onset Hypogonadism in JapanHisanori Taniguchi MD PhD0Tadashi Matsuda MD1Kansai Medical University, Hirakata, Osaka, JapanKansai Medical University, Hirakata, Osaka, JapanThe adequate criteria for late-onset hypogonadism (LOH) diagnosis, including serum testosterone levels, type (total or free testosterone) and duration of androgen replacement therapy, and evaluations of treatment effectiveness remain controversial. To evaluate the current status of medical treatment for LOH in Japan, the first nationwide survey were performed. A total of 35 questionnaires answered by urologists in high-volume facilities were analyzed. The median numbers of patients with hypogonadism-related symptoms per month were 10. Aging Male Symptom Score, International Index of Erectile Function, and International Prostate Symptom Score questionnaires were widely used for questionnaires. The diagnostic criteria for LOH varied. Among the patients who presented with hypogonadism-related symptoms, the mean proportion of patients undergoing treatment for LOH was 62.3%. In Japan, LOH was treated not only with testosterone enanthate injections or testosterone ointment but also with Kampo medicine. In many facilities, LOH treatment effectiveness was assessed after a 3-month period. Efficacy was assessed in different ways. Treatment effectiveness rate ranged from 30% to 80%. The duration of LOH treatment was not fixed and was established individually by both the patient and treating physician. This study showed that the real clinical practices for LOH are very diverse, and a general consensus is needed.https://doi.org/10.1177/1557988316681668 |
| spellingShingle | Hisanori Taniguchi MD PhD Tadashi Matsuda MD Multi-Institutional Survey of Medical Treatment for Late-Onset Hypogonadism in Japan American Journal of Men's Health |
| title | Multi-Institutional Survey of Medical Treatment for Late-Onset Hypogonadism in Japan |
| title_full | Multi-Institutional Survey of Medical Treatment for Late-Onset Hypogonadism in Japan |
| title_fullStr | Multi-Institutional Survey of Medical Treatment for Late-Onset Hypogonadism in Japan |
| title_full_unstemmed | Multi-Institutional Survey of Medical Treatment for Late-Onset Hypogonadism in Japan |
| title_short | Multi-Institutional Survey of Medical Treatment for Late-Onset Hypogonadism in Japan |
| title_sort | multi institutional survey of medical treatment for late onset hypogonadism in japan |
| url | https://doi.org/10.1177/1557988316681668 |
| work_keys_str_mv | AT hisanoritaniguchimdphd multiinstitutionalsurveyofmedicaltreatmentforlateonsethypogonadisminjapan AT tadashimatsudamd multiinstitutionalsurveyofmedicaltreatmentforlateonsethypogonadisminjapan |